menu
    • menu

    Company profile for Formosa Laboratories

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    Contact Supplier

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspections from regulatory authorities around the world, Formosa now provides CDMO service extending from APIs and ADCs (Antibody Drug Conjugates) to cytotoxic and non-cytotoxic injectables of aseptic liquid filling and lyophilization. Formosa Laboratories ...
    Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspections from regulatory authorities around the world, Formosa now provides CDMO service extending from APIs and ADCs (Antibody Drug Conjugates) to cytotoxic and non-cytotoxic injectables of aseptic liquid filling and lyophilization. Formosa Laboratories is able to offer full-service GMP manufacturing for drug substance, ADCs and drug product with its API and injectable facilities that accommodates small molecules, biologics and ADCs etc.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Formosa LaboratoriesTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    No. 36, Hoping Street, Louchu, Taoyuan 338002
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.formosalab.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 274

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaConnecting People, Mentalities & MarketsConnecting People, Mentalities & Markets

    Connecting People, Mentalities & Markets
    Connecting People, Mentalities & Markets

    reelConnecting People, Mentalities & Markets

    This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

    Impressions: 332

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 519

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

    #PharmaFlow by PHARMACOMPASS
    15 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Formosa Labs Q3 Earnings: NT$0.19 EPS Vs NT$0.95 Loss In 2023
    Formosa Labs Q3 Earnings: NT$0.19 EPS Vs NT$0.95 Loss In 2023

    18 Nov 2024

    // PRESS RELEASE

    https://simplywall.st/stocks/tw/pharmaceuticals-biotech/twse-4746/formosa-laboratories-shares/news/formosa-laboratories-third-quarter-2024-earnings-eps-nt019-v

    PRESS RELEASE
    18 Nov 2024
    Share Share
    Formosa Labs Passes FDA Inspection For Breast Cancer Drug
    Formosa Labs Passes FDA Inspection For Breast Cancer Drug

    19 Sep 2024

    // PRESS RELEASE

    https://www.taiwan-healthcare.org/en/news-detail?id=0sk1c4ep3bulsje9

    PRESS RELEASE
    19 Sep 2024
    Share Share
    Formosa Passes 1st FDA GMP Check For High-Potency Injectables
    Formosa Passes 1st FDA GMP Check For High-Potency Injectables

    16 Sep 2024

    // PRESS RELEASE

    https://www.formosalab.com/news-list-page608

    PRESS RELEASE
    16 Sep 2024
    Share Share
    Formosa Pharma Licenses Clobetasol Ophthalmic Drug To Apotex
    Formosa Pharma Licenses Clobetasol Ophthalmic Drug To Apotex

    05 Sep 2024

    // PRESS RELEASE

    https://www.formosalab.com/news-list-page612

    PRESS RELEASE
    05 Sep 2024
    Share Share
    Formosa Labs Completes Acquisition of Synchem
    Formosa Labs Completes Acquisition of Synchem

    04 Jun 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-06-04/formosa-labs-completes-acquisition-of-synchem/

    CONTRACT PHARMA
    04 Jun 2024
    Share Share
    Formosa Acquires Synchem, Expands North American CDMO Footprint
    Formosa Acquires Synchem, Expands North American CDMO Footprint

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-laboratories-completes-the-acquisition-of-synchem-to-expand-north-american-cdmo-footprint-302160495.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Formosa Laboratories and get a quotation

    Formosa Laboratories is a supplier offers 69 products (APIs, Excipients or Intermediates).

    Find a price of Calcitriol bulk with DMF, CEP, JDMF offered by Formosa Laboratories

    Find a price of Temozolomide bulk with DMF, CEP, JDMF offered by Formosa Laboratories

    Find a price of Calcifediol bulk with DMF, CEP offered by Formosa Laboratories

    Find a price of Calcipotriol bulk with DMF, CEP offered by Formosa Laboratories

    Find a price of Leflunomide bulk with DMF, CEP offered by Formosa Laboratories

    Find a price of Levonorgestrel bulk with DMF, JDMF offered by Formosa Laboratories

    Find a price of Linezolid bulk with DMF, JDMF offered by Formosa Laboratories

    Find a price of Montelukast Sodium bulk with DMF, CEP offered by Formosa Laboratories

    Find a price of Abemaciclib bulk with DMF offered by Formosa Laboratories

    Find a price of Alfacalcidol bulk with JDMF offered by Formosa Laboratories

    Find a price of Anastrozole bulk with DMF offered by Formosa Laboratories

    Find a price of Apraclonidine Hydrochloride bulk with DMF offered by Formosa Laboratories

    Find a price of Avobenzona bulk with DMF offered by Formosa Laboratories

    Find a price of Balsalazide Disodium bulk with DMF offered by Formosa Laboratories

    Find a price of Benzonatate bulk with DMF offered by Formosa Laboratories

    Find a price of Betamethasone bulk with JDMF offered by Formosa Laboratories

    Find a price of Calcitriol bulk with CEP offered by Formosa Laboratories

    Find a price of Calcium Acetate bulk with DMF offered by Formosa Laboratories

    Find a price of Capsaicin bulk with DMF offered by Formosa Laboratories

    Find a price of Colesevelam Hydrochloride bulk with DMF offered by Formosa Laboratories

    Find a price of Colestipol bulk with DMF offered by Formosa Laboratories

    Find a price of DOTA bulk with DMF offered by Formosa Laboratories

    Find a price of Doxcercalciferol bulk with DMF offered by Formosa Laboratories

    Find a price of Elagolix Sodium bulk with DMF offered by Formosa Laboratories

    Find a price of Eribulin bulk with DMF offered by Formosa Laboratories

    Find a price of Ferric Carboxymaltose bulk with DMF offered by Formosa Laboratories

    Find a price of Fondaparinux Sodium bulk with DMF offered by Formosa Laboratories

    Find a price of Gadobutrol bulk with DMF offered by Formosa Laboratories

    Find a price of Gadodiamide bulk with JDMF offered by Formosa Laboratories

    Find a price of Gadoterate Meglumine bulk with DMF offered by Formosa Laboratories

    Find a price of Gimeracil-13C3 bulk with JDMF offered by Formosa Laboratories

    Find a price of Iloperidone bulk with DMF offered by Formosa Laboratories

    Find a price of Imatinib Mesylate bulk with DMF offered by Formosa Laboratories

    Find a price of Ixabepilone bulk with DMF offered by Formosa Laboratories

    Find a price of Lapatinib Ditosylate bulk with DMF offered by Formosa Laboratories

    Find a price of Linezolid bulk with JDMF offered by Formosa Laboratories

    Find a price of Maxacalcitol bulk with JDMF offered by Formosa Laboratories

    Find a price of Meprobamate bulk with DMF offered by Formosa Laboratories

    Find a price of Mifepristone bulk with DMF offered by Formosa Laboratories

    Find a price of Mycophenolate Mofetil bulk with DMF offered by Formosa Laboratories

    Find a price of Mycophenolate Sodium bulk with DMF offered by Formosa Laboratories

    Find a price of Mycophenolic Acid bulk with DMF offered by Formosa Laboratories

    Find a price of Nalbuphine Sebacate bulk with DMF offered by Formosa Laboratories

    Find a price of Nexact-88 bulk with DMF offered by Formosa Laboratories

    Find a price of Nintedanib Esylate bulk with DMF offered by Formosa Laboratories

    Find a price of Nonivamide bulk with JDMF offered by Formosa Laboratories

    Find a price of Orlistat bulk with DMF offered by Formosa Laboratories

    Find a price of Oteracil Potassium bulk with JDMF offered by Formosa Laboratories

    Find a price of Paricalcitol bulk with DMF offered by Formosa Laboratories

    Find a price of Patiromer Sorbitex Calcium bulk with DMF offered by Formosa Laboratories

    Find a price of Pazopanib Hydrochloride bulk with DMF offered by Formosa Laboratories

    Find a price of Rucaparib Camsylate bulk with DMF offered by Formosa Laboratories

    Find a price of Sevelamer Carbonate bulk with DMF offered by Formosa Laboratories

    Find a price of Sevelamer Hydrochloride bulk with DMF offered by Formosa Laboratories

    Find a price of Taltirelin bulk with JDMF offered by Formosa Laboratories

    Find a price of Tegafur bulk with JDMF offered by Formosa Laboratories

    Find a price of Teriflunomide bulk with DMF offered by Formosa Laboratories

    Find a price of Ulipristal Acetate bulk with DMF offered by Formosa Laboratories

    Find a price of Vitamin D bulk with DMF offered by Formosa Laboratories

    Find a price of Ecamsule bulk offered by Formosa Laboratories

    Find a price of Fludiazepam bulk offered by Formosa Laboratories

    Find a price of Gimeracil bulk offered by Formosa Laboratories

    Find a price of Iloperidone bulk offered by Formosa Laboratories

    Find a price of Mycophenolate Mofetil bulk offered by Formosa Laboratories

    Find a price of Oteracil bulk offered by Formosa Laboratories

    Find a price of Paricalcitol bulk offered by Formosa Laboratories

    Find a price of Tasimelteon bulk offered by Formosa Laboratories

    Find a price of Tetraferric tricitrate decahydrate bulk offered by Formosa Laboratories

    Find a price of XAV-939 bulk offered by Formosa Laboratories

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search